# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: modern shifted

## Reason for visit

Primary care visit for breathlessness on exertion and ankle swelling. **S**

## Historical basis

- Susan B. Anthony was born on February 15, 1820, in Adams, Massachusetts, the second child of Daniel and Lucy Read Anthony. **D**
- Anthony voted in the 1872 presidential election, was arrested at her Rochester home, and was convicted at Canandaigua, New York; she refused to pay the $100 fine. **D**
- Her father, Daniel Anthony, who had not had a day's illness in forty years, was suddenly stricken in November 1862 with what was called acute neuralgia of the stomach and died two weeks later, on November 25, 1862, at 69. **D**
- Her 1898 biography describes a long-lived family: her mother died at eighty-six, her paternal grandfather lived past ninety-seven, and both maternal grandparents died in their eighty-fourth year. **D**
- In January 1891, after weeks of what seemed a persistent la grippe, Anthony collapsed at the Garrison home in Brookline, Massachusetts; pneumonia threatened and she kept to her room for a week. **D**
- On July 26, 1895, near the end of an address at Lakeside, Ohio, Anthony stopped abruptly and fainted; from July 30 she spent a month in bed with what was called nervous prostration, described as her first serious illness in seventy-five years. **D**
- Her biographer described her daily habits in the late 1890s: a cold sponge bath each morning, simple food, tea and coffee in moderation, a rest after meals and an hour's rest each afternoon, and fresh air and exercise every day, walking from the station after a day on the train. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Breathlessness and ankle swelling after travel threaten her lecture schedule. **S**
- Does not want to be kept in bed or slowed down by treatment. **S**

## Strengths and supports

- Supports: sister, nieces, and a close circle of younger colleagues **S**

## Medications and allergies

- Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- January 1891: Prolonged la grippe with collapse; pneumonia threatened and she kept to her room for a week **D** (CLM-0005)
- July 26, 1895: Fainted while speaking at Lakeside, Ohio, followed by a month in bed with what was called nervous prostration; no cardiac evaluation recorded **D** (CLM-0006)

## Procedures and immunizations

- 2026-03-16 to 2026-03-16: 12-lead electrocardiogram: sinus rhythm, left ventricular hypertrophy by voltage, no atrial fibrillation **S**
- 2025-10-06: High-dose influenza vaccine, 2025-2026 season **S**
- 2022-11-14: Recombinant zoster vaccine, two-dose series completed **S**
- 2020-05-11: Tdap vaccine **S**

## Family history

- father: Died November 25, 1862, at 69, after a sudden two-week illness then called acute neuralgia of the stomach **D** (CLM-0003)
- mother: Died at 86; cause not recorded in the cited source **D** (CLM-0004)
- paternal grandfather: Lived past 97; cause of death not recorded in the cited source **D** (CLM-0004)
- maternal grandmother: Died in her eighty-fourth year; cause not recorded in the cited source **D** (CLM-0004)
- maternal grandfather: Died in his eighty-fourth year; cause not recorded in the cited source **D** (CLM-0004)

## Measurements

NT-proBNP: 1650 pg/mL (high); Sodium: 138 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.88 mg/dL; eGFR: 64 mL/min/1.73 m²; Glucose: 96 mg/dL; Magnesium: 2 mg/dL; Hemoglobin: 12.4 g/dL; Ferritin: 140 ng/mL; Transferrin saturation: 24%; TSH: 2.4 mIU/L; HbA1c: 5.5%; LDL cholesterol: 96 mg/dL; ALT: 18 U/L; KCCQ-12 overall summary: 52; PHQ-2: 0. All results are synthetic.

BP 158/86 mmHg; pulse 84 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 95% on room air; weight 58.5 kg; BMI 21.5 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, oriented, quick, and forthright; impatient with being ill; Mood euthymic; PHQ-2 negative. Functional status: Independent in all activities of daily living; breathless after one flight of stairs or a long station platform at intake; NYHA class II to III; Walking two miles a day again and back on the lecture circuit by the six-month review. Physical examination is intentionally limited. **S**

## Assessment

1. Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failure; status draft. **S**
2. Hypertensive heart disease with heart failure; status draft. **S**

## Plan

- Treat congestion with furosemide and start empagliflozin for HFpEF; move to as-needed furosemide guided by daily weights once euvolemic. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Add low-dose spironolactone for HFpEF with blood pressure above target once potassium and kidney function are stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Cardiology referral to confirm the diagnosis, review the echocardiogram, and look for specific causes such as amyloidosis or valve disease. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Check a basic metabolic panel and magnesium one to two weeks after starting or changing diuretic, SGLT2 inhibitor, or mineralocorticoid antagonist therapy, then every three to six months; KCCQ-12 every three to six months. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Daily weights, sodium moderation, a written travel plan for weight gain, and continued daily walking; refer to cardiac rehabilitation if exercise tolerance plateaus. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Pneumococcal and RSV vaccination and a yearly high-dose influenza vaccine to lower the risk of respiratory infection in heart failure. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026), Aether Forge
